XTX Topco Ltd Purchases New Position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

XTX Topco Ltd acquired a new position in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA) during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm acquired 7,719 shares of the company’s stock, valued at approximately $245,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. SG Americas Securities LLC increased its stake in shares of IDEAYA Biosciences by 411.3% during the second quarter. SG Americas Securities LLC now owns 11,775 shares of the company’s stock valued at $413,000 after buying an additional 9,472 shares during the period. Nisa Investment Advisors LLC raised its holdings in shares of IDEAYA Biosciences by 38.4% in the 2nd quarter. Nisa Investment Advisors LLC now owns 3,340 shares of the company’s stock valued at $117,000 after purchasing an additional 927 shares in the last quarter. Bank of New York Mellon Corp lifted its position in shares of IDEAYA Biosciences by 43.0% in the 2nd quarter. Bank of New York Mellon Corp now owns 316,492 shares of the company’s stock worth $11,112,000 after purchasing an additional 95,129 shares during the period. Rhumbline Advisers increased its holdings in IDEAYA Biosciences by 9.7% during the second quarter. Rhumbline Advisers now owns 105,797 shares of the company’s stock valued at $3,715,000 after buying an additional 9,387 shares during the period. Finally, Fiera Capital Corp raised its stake in IDEAYA Biosciences by 22.6% in the second quarter. Fiera Capital Corp now owns 1,335,410 shares of the company’s stock worth $46,886,000 after buying an additional 246,010 shares in the last quarter. 98.29% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several analysts have issued reports on IDYA shares. Wedbush reaffirmed an “outperform” rating and set a $52.00 target price on shares of IDEAYA Biosciences in a research report on Tuesday. Leerink Partnrs downgraded shares of IDEAYA Biosciences from a “strong-buy” rating to a “hold” rating in a report on Tuesday, November 5th. Leerink Partners cut shares of IDEAYA Biosciences from an “outperform” rating to a “market perform” rating and lowered their price target for the company from $41.00 to $27.00 in a report on Tuesday, November 5th. Cantor Fitzgerald reiterated an “overweight” rating on shares of IDEAYA Biosciences in a research note on Tuesday. Finally, Citigroup lowered their target price on shares of IDEAYA Biosciences from $60.00 to $58.00 and set a “buy” rating for the company in a research note on Tuesday, August 27th. Two investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, IDEAYA Biosciences has an average rating of “Moderate Buy” and a consensus price target of $53.67.

IDEAYA Biosciences Price Performance

Shares of IDYA stock opened at $25.59 on Thursday. The business has a fifty day moving average of $28.49 and a 200 day moving average of $34.17. IDEAYA Biosciences, Inc. has a 1 year low of $24.72 and a 1 year high of $47.74. The firm has a market capitalization of $2.21 billion, a price-to-earnings ratio of -10.98 and a beta of 0.79.

IDEAYA Biosciences (NASDAQ:IDYA) last announced its quarterly earnings data on Monday, November 4th. The company reported ($0.60) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.63) by $0.03. During the same period in the previous year, the firm earned ($0.46) earnings per share. As a group, equities research analysts expect that IDEAYA Biosciences, Inc. will post -2.45 earnings per share for the current year.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.